乐天堂fun88

You are here： Home  >> Technical Services  >> Scientific Research Services

Scientific Research Services


I. Service content:

 

II. Core benefits:

•  The onlystable transfection processretroviralEnjoy discounts when repurchasingretroviral vectors
•  If commercialization of the resultsis required later,retroviral vectorsand cell products can beseamlessly integrated intoGMP-levelproduction servicesultra-low cost ; •  Retroviral vectorscan carrylarge target fragmentsup to 7kb ; •  ForNK cellsthat are difficult to infect withlentivirusesthe transduction efficiencyusingretroviralover 50%,with a viability rate of over 95%; •  A professional technical team providesfull-process technical supportto ensure the smooth progress of the project.



III. Case Study
 


IV. Service Cases

Shenzhen Cell Valley has launched a comprehensive collaboration with Academician Tian Zhigang's team at Enkasai Pharmaceuticals, focusing on CAR-NK drug development projects and assisting in the optimization, development, and production of retroviral vectors to accelerate the development of therapeutic drugs.

Shenzhen Cell Valley has launched a comprehensive collaboration with Academician Yan Xiyun's team at the Institute of Biophysics, Chinese Academy of Sciences, on retroviral vector preparation, CAR-T cell preparation , and related technology transfer. This collaboration aims to promote the industrialization of high-quality research results, help good products move from research institutes to the market, and create a new business model for CAR-T cell products using domestically produced retroviral vectors.


About Us
Scan to follow our latest newsScan to follow our latest news
Contact Us
400-800-1266

Working hours: Monday to Friday, 9:00-18:00

Contact：Ms. Lai

Email：laijiaqi@wfzydp.com

Address：No. 1, Rongtian Road, Jinsha Community, Kengzi Street, Pingshan District, Shenzhen, China (Hepure Biomedical Ecological Park)

Shenzhen Cell Valley Biopharmaceutical Co., Ltd. is a leading one-stop comprehensive outsourcing service provider for China’s cell and gene therapy industry. It is also among the first domestic CRO/CDMO enterprises to hold GMP-compliant industrial production capabilities for clinical-grade retroviral vectors. As a key project for the construction of Shenzhen’s public technical service platform for CRO/CDMO, the company has been listed in the city’s newly announced "20+8" strategic emerging industries initiative.
Shenzhen Cell Valley is equipped with the capacity to conduct standardized and industrialized production of GMP-grade cellular products including CAR-T cells. Its core production lines cover a full spectrum of cellular products such as CAR-T, CAR-NK, CAR-M, γδT, TIL and TCR-T. In addition, the company runs production lines for a diverse range of viral vectors (including RVV, LVV and AAV) and non-viral vectors, as well as for cellular raw materials for therapeutic development—such as exosomes, genetically engineered antibodies, cytokines, oncolytic viruses and vaccines.
 Copyright 粤ICP备2024168379号 互联网药品信息服务资格证书：(粤)-非经营性-2022-0426  Technical Support：YouDian Software